Dr Kaitin writes and speaks frequently on factors that contribute to the slow pace and high cost of pharmaceutical R&amp,D and the impact of efforts to speed the drug development process.

How CDMOs are reshaping pharmaceutical partnerships through friendshoring, risk-sharing economics, and specialized development capabilities.

Trump has signed a pivotal executive order aimed at revitalizing the U.S. pharmaceutical manufacturing sector. This directive ...

U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb ...

Sustainability-by-design in bioprocess development, according to Adam Goldstein, senior director of R&D Collaborations at ...

This article is authored by Aditya Sharma, head, Process Solutions, India Region, Merck Life Science, New Delhi.

During a recent panel discussion sponsored by Purdue University, industry leaders explain how the technology is revolutionizing drug development and production ...

Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines ...

The pharmaceutical trade is complicated ... of the way the business functions: Generic drugs don’t require high costs for research and development, but drug companies only profit if they ...

and partnerships between pharmaceutical companies and AI technology providers. By analyzing enormous volumes of biological and chemical data, AI algorithms and data analytic approaches are ...